TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference

Rhea-AI Summary

TCR² Therapeutics (Nasdaq: TCRR) announced a participation of Ian Somaiya and Alfonso Quintás-Cardama in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 AM ET.

This fireside chat will be accessible via a live webcast on the Company's Investors page, with an archived replay available for 30 days post-event. TCR² focuses on innovative T cell therapies for cancer, including its lead candidates gavo-cel for solid tumors and TC-110 for hematological malignancies.

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, and Alfonso Quintás-Cardama, M.D., Chief Medical Officer of TCR² Therapeutics, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 2021 at 8:00am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is TCR² Therapeutics participating in on February 24, 2021?

TCR² Therapeutics will participate in the SVB Leerink 10th Annual Global Healthcare Conference.

Who will represent TCR² Therapeutics at the conference?

Ian Somaiya, Chief Financial Officer, and Alfonso Quintás-Cardama, M.D., Chief Medical Officer, will represent TCR² Therapeutics.

How can I access the TCR² Therapeutics conference presentation?

The presentation can be accessed via a live webcast on TCR² Therapeutics' Investors page.

What are TCR² Therapeutics' main product candidates?

The main product candidates are gavo-cel for solid tumors and TC-110 for hematological malignancies.

How long will the webcast of TCR² Therapeutics' presentation be available?

An archived replay of the presentation will be available for at least 30 days following the event.